Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04884191 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT04884191: Completed Phase 2 study, sponsored by CTI BioPharma.
NCT04884191 is a Phase 2 study that has completed, run by CTI BioPharma. The registered enrollment target is 165 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04884191, a Phase 2 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System \[DIPSS\] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.
Primary Outcome
Number of patients achieving a ≥ 35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans
Interventions
- DRUG Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2019-09-04 |
| Phase | Phase 2 |
What the finished NCT04884191 record still lists
NCT04884191 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher).
The record links to 0 conditions, and to 1 intervention - of which Pacritinib is the first listed.
NCT04884191 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04884191 about?
NCT04884191 is a clinical study titled "Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib". This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System \[DIPSS\] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage se...
What is the current status of trial NCT04884191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2017-07-31. Estimated completion is 2019-09-04.
What interventions are being tested in trial NCT04884191?
The interventions under investigation include: Pacritinib (DRUG).
Who is sponsoring clinical trial NCT04884191?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04884191's enrollment target sits among peer trials
165 410th of 2000 higher than 1,588 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI